{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-015037","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.686381+00:00","generated_at":"2026-06-03T21:44:29.109595+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Serina Therapeutics appoints Dr. Simba Gill as Executive Chairman","bullets":["Dr. Simba Gill appointed Executive Chairman effective April 12, 2024.","Annual cash fee of $300,000 and grant of 295,300 stock options under 2024 Equity Incentive Plan.","Dr. Gill has over 35 years of biotech leadership including Maxygen, Systemix, Boehringer Mannheim, Celltech.","Five-year post-termination non-compete and non-solicitation covenants apply."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-015037","json":"https://secwatch.observer/filing/0001493152-24-015037.json","markdown":"https://secwatch.observer/filing/0001493152-24-015037.md","text":"https://secwatch.observer/filing/0001493152-24-015037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224015037/0001493152-24-015037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224015037/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:44:29.109595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf0c39d001","claim":"Simba Gill was appointed as Executive Chairman at Serina Therapeutics, Inc..","evidence_excerpt":"On April 17, 2024, Serina Therapeutics, Inc. (the “Company”) announced the appointment of Simba Gill, Ph.D., as the Company’s Chairman of the Board of Directors, effective as of April 12, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224015037/0001493152-24-015037-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}